368 related articles for article (PubMed ID: 25957829)
1. Ipilimumab-induced hypophysitis: review of the literature.
Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
4. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
6. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Dillard T; Yedinak CG; Alumkal J; Fleseriu M
Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
12. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
[TBL] [Abstract][Full Text] [Related]
15. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
16. [Lymphocytic hypophysitis due to ipilimumap therapy].
Thomsen HH
Ugeskr Laeger; 2012 Jun; 174(26):1829-30. PubMed ID: 22735122
[TBL] [Abstract][Full Text] [Related]
17. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
[TBL] [Abstract][Full Text] [Related]
18. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
19. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.
Torino F; Barnabei A; Paragliola RM; Marchetti P; Salvatori R; Corsello SM
Eur J Endocrinol; 2013 Dec; 169(6):R153-64. PubMed ID: 24001893
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]